Articles

Shortening the duration of antimicrobial therapy to that recommended in guidelines may reduce the risk for collateral damage due to Clostridium difficile infection. Read More ›

The researchers assessed the impact of antimicrobial stewardship program interventions in elderly patients on 30-day readmissions due to treatment failure and decreased antibiotic expenditures per adjusted patient-day. Read More ›

A pooled analysis showed favorable safety results from phase 3 studies of omadacycline, a new once-daily intravenous/oral therapy for the monotherapy of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Read More ›

Pooled safety data of eravacycline in 3 comparator-controlled studies for the treatment of complicated intra-abdominal infections showed that it was generally well-tolerated compared with ertapenem and meropenem. Read More ›

Evaluation of lefamulin, a novel oral antimicrobial, in patients with community-acquired bacterial pneumonia demonstrated noninferiority for both the US Food and Drug Administration and European Medicines Agency efficacy end points versus oral moxifloxacin. Read More ›

In patients with community-acquired pneumonia, a regimen that includes a fluoroquinolone (and possibly a macrolide) may reduce mortality compared with beta-lactams (with or without a beta-lactamase inhibitor) and cephalosporins alone. Read More ›

A protocol to guide rational antibiotic therapy in patients receiving extracorporeal membrane oxygenation can lead to a reduction in the use of specific antibiotics, but paradoxically, may increase overall antibiotic use. Read More ›

Accurate anatomic subtyping, optimal diagnostic imaging, and molecular classification are among the most pressing needs with NETs. Read More ›

The future of PRRT lies in its use in combination therapies, including PRRT with chemotherapy, immunotherapy, and as neoadjuvant/adjuvant therapy with surgery. Read More ›

Targeted alpha-particle therapy is in development for targeted radionuclide therapy of NETs, employing alpha decay to treat diseased tissue at close proximity. Read More ›